Journal of Dermatology最新文献

{"title":"Minimally Invasive Phenol Treatment for Pilonidal Sinus: A Single-Center Case Series From Japan","authors":"Sayo Komiyama,&nbsp;Masaaki Sakumoto,&nbsp;Akiko Kaneshima,&nbsp;Takuya Miyagi,&nbsp;Sayaka Yamaguchi,&nbsp;Teruki Yanagi","doi":"10.1111/1346-8138.70354","DOIUrl":"10.1111/1346-8138.70354","url":null,"abstract":"<div>\u0000 \u0000 <p>Pilonidal sinus is a chronic inflammatory condition of the natal cleft that commonly affects young adults. Conventional surgical treatments, such as wide excision and flap reconstruction, are associated with large wounds and prolonged recovery. Phenol treatment has been reported as a minimally invasive alternative in several countries; however, clinical experience in Japan remains limited. We retrospectively reviewed patients with pilonidal sinus who underwent phenol treatment at our institution between 2020 and 2025. After excision of the midline pits and curettage of the sinus tract, undiluted phenol was injected into the cavity and subsequently neutralized with ethanol. Clinical data, including patient characteristics, number of pits, operative time, postoperative hospital stay, complications, and recurrence, were analyzed. A total of 11 patients were included in the study. The median age was 27 years (range, 13–50), and 10 patients were male. The median number of pits was 3 (range, 1–5). The median operative time was 32 min (range, 19–56), and the median postoperative hospital stay was 2 days (range, 1–6). Postoperative bleeding occurred in two patients and was successfully managed conservatively. No recurrence was observed during the follow-up period (median, 331 days; range, 100–979). Phenol treatment for pilonidal sinus appears to be a simple and minimally invasive procedure associated with short hospitalization and favorable short-term outcomes. This technique may represent a useful treatment option for pilonidal sinus in Japan.</p>\u0000 </div>","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"53 8","pages":"1203-1207"},"PeriodicalIF":2.3,"publicationDate":"2026-08-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148267701","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hypopigmented Mycosis Fungoides With Childhood-Onset and Middle-Aged Onset: Two Case Reports Focusing on the Cutaneous Immune Microenvironment","authors":"Yoko Yahagi,&nbsp;Taku Fujimura,&nbsp;Arisa Yoshida,&nbsp;Yoshihide Asano","doi":"10.1111/1346-8138.70343","DOIUrl":"10.1111/1346-8138.70343","url":null,"abstract":"<div>\u0000 \u0000 <p>Hypopigmented mycosis fungoides (MF) is a rare clinical variant of MF that often presents in childhood or young adulthood and is typically associated with an indolent course. In contrast to classic MF, hypopigmented MF frequently shows a CD8⁺ T-cell-predominant phenotype, and cytotoxic immune responses have been implicated in melanocyte injury; however, the cutaneous immune microenvironment across different ages of onset remains incompletely characterized. We reported two cases of hypopigmented MF with distinct ages of disease onset and evaluated lesional immune profiles by immunohistochemistry, focusing on CD8, FOXP3, CXCL10, and CCL19. In both cases, the epidermotropic infiltrate was CD8-positive T-cell dominant, accompanied by scarce FOXP3-positive cells and increased expression of CXCL10 together with CCL19. These shared features support the concept that a Tc1-associated cytotoxic immune milieu, accompanied by scarce FOXP3-positive cells, may be associated with hypopigmentation in hypopigmented MF, irrespective of the age at clinical presentation.</p>\u0000 </div>","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"53 8","pages":"1194-1197"},"PeriodicalIF":2.3,"publicationDate":"2026-08-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148207412","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Phenotypic Analysis of 26 Cultured TILs Derived From Japanese Melanoma Tissues","authors":"Rena Oguma,&nbsp;Shigeru Koizumi,&nbsp;Yuka Saeki,&nbsp;Kazuhiro Aoyama,&nbsp;Yu Kawahara,&nbsp;Takamitsu Matsuzawa,&nbsp;Noriko Saito,&nbsp;Ayako Oikawa,&nbsp;Katsushige Kawase,&nbsp;Akiko Honobe-Tabuchi,&nbsp;Ryosuke Tagashira,&nbsp;Chie Urasaki,&nbsp;Yaei Togawa,&nbsp;Tatsuyoshi Kawamura,&nbsp;Toyoyuki Hanazawa,&nbsp;Shusuke Kawashima,&nbsp;Takashi Inozume","doi":"10.1111/1346-8138.70346","DOIUrl":"10.1111/1346-8138.70346","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Purpose</h3>\u0000 \u0000 <p>Tumor-infiltrating lymphocyte (TIL) therapy has attracted increasing attention as a promising next-generation cancer immunotherapy that may overcome some limitations of current immune checkpoint inhibitors. However, the phenotypic characteristics and tumor reactivity of TILs derived from Japanese melanoma tissues remain insufficiently investigated. This study aimed to evaluate the feasibility of expanding TILs from Japanese melanoma specimens and to characterize their phenotype and autologous tumor reactivity.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>TILs were expanded from 26 Japanese melanoma specimens, including tumors derived from primary and mucosal lesions. The phenotypes of cultured TILs were assessed, and reactivity against autologous tumor cells was evaluated in 9 available TIL samples.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>TILs were successfully expanded from Japanese melanoma tissues, consistent with previous reports from the United States. The phenotypes of cultured TILs varied substantially among cases. Among the 9 TIL samples tested for reactivity against autologous tumor cells, MHC class I-restricted specific reactivity was detected in 7 samples, including 1 sample derived from mucosal melanoma. No clear association was observed between autologous tumor reactivity and the proportion of CD3⁺CD8⁺ T cells or the expression of specific markers on CD3⁺CD8⁺ T cells.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>This study is the first to characterize cultured TILs established from a series of Japanese melanoma patients. These findings suggest that the expansion of tumor-reactive TILs from Japanese melanoma tissues is feasible and may provide a basis for the development of TIL therapy in Japan.</p>\u0000 </section>\u0000 </div>","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"53 8","pages":"1153-1161"},"PeriodicalIF":2.3,"publicationDate":"2026-08-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148221489","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Incidence Trends and Severe in-Hospital Outcomes of Pemphigus Vulgaris: A Nationwide Cohort Study","authors":"Rachot Wongjirattikarn,&nbsp;Kumutnart Chanprapaph,&nbsp;Pawinee Rerknimitr,&nbsp;Leena Chularojanamontri,&nbsp;Charoen Choonhakarn,&nbsp;Suteeraporn Chaowattanapanit,&nbsp;Thanaphon Anutraungkool,&nbsp;Nathaphop Chaichaya,&nbsp;Narachai Julanon","doi":"10.1111/1346-8138.70331","DOIUrl":"10.1111/1346-8138.70331","url":null,"abstract":"<div>\u0000 \u0000 <p>Contemporary population-based data on incidence trends and in-hospital outcomes of pemphigus vulgaris remain limited, particularly in Southeast Asia. This study aimed to characterize incidence patterns and identify factors associated with severe in-hospital outcomes. We conducted a nationwide retrospective cohort study using Thailand's national administrative health database from 2015 to 2024. Incident cases were defined using a two-year washout period. Crude and age-standardized incidence rates were estimated, and temporal trends were evaluated using Poisson regression. Hospitalization analyses were restricted to index hospitalizations. Severe in-hospital outcomes were defined as a composite of in-hospital mortality, invasive mechanical ventilation, renal replacement therapy, or shock. Associations with severe in-hospital outcomes were evaluated using multivariable logistic regression, with sensitivity analyses accounting for repeated admissions using generalized estimating equations. A total of 2 542 incident adult cases were identified, corresponding to a mean annual incidence of 6.03 per 1 000 000 population. Incidence increased over time (adjusted incidence rate ratio 1.20; 95% CI 1.18–1.22), was higher with advancing age, and among females (female-to-male ratio 1.41:1). Increasing age-standardized incidence rates suggested that the temporal increase was not fully explained by population aging. This trend was accompanied by increasing annual hospitalizations. Among 1 537 index hospitalizations, 8.1% experienced severe in-hospital outcomes. Acute kidney injury, malnutrition, and infection were associated with severe in-hospital outcomes. In sensitivity analyses accounting for repeated admissions, advancing age and cardiovascular comorbidity were also associated with increased risk. Pemphigus vulgaris demonstrates a rising incidence beyond the effects of population aging, accompanied by increasing hospitalizations and a growing burden of severe in-hospital outcomes. These findings support early identification of high-risk patients and appropriate clinical management.</p>\u0000 </div>","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"53 8","pages":"1142-1152"},"PeriodicalIF":2.3,"publicationDate":"2026-08-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148059250","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictors of Immunosuppressive Treatment in Cutaneous Arteritis: Analysis of Clinical Characteristics in 42 Patients","authors":"Haruka Arakawa,&nbsp;Tomoya Watanabe,&nbsp;Yasushi Ototake,&nbsp;Saya Imai,&nbsp;Hisho Kawamura,&nbsp;Izumi Moteki,&nbsp;Asami Akita,&nbsp;Miwa Kanaoka,&nbsp;Miyu Kobayashi,&nbsp;Yusuke Saigusa,&nbsp;Yukie Yamaguchi","doi":"10.1111/1346-8138.70339","DOIUrl":"10.1111/1346-8138.70339","url":null,"abstract":"<div>\u0000 \u0000 <p>Cutaneous arteritis is a necrotizing vasculitis of medium-sized vessels in the skin for which no established criteria exist to guide the initiation of systemic treatment. This study aimed to identify the clinical and laboratory markers associated with the initiation of immunosuppressive treatments, including systemic corticosteroids. This retrospective chart review included 42 patients with cutaneous arteritis treated at the Department of Dermatology, Yokohama City University Hospital, from 2010 to 2023. Clinical manifestations and laboratory and imaging data were collected. Univariable and multivariable analyses were performed to identify the risk factors associated with the initiation of immunosuppressive treatment. Twenty-five patients with cutaneous arteritis (five men, 20 women) were included in this study. Of these, 14 patients received systemic corticosteroids and 11 were treated with additional immunosuppressive drugs. The Youden index analysis indicated that the thresholds of systemic corticosteroid induction were patients older than 43 years and platelet counts more than 340 000/μL. Univariable Firth logistic regression analysis showed numbness in the lower limbs, older age at onset, elevated platelet counts, and D-dimer levels (≥ 1 μg/mL) as risk factors for systemic corticosteroids. Our analysis identified several risk factors, such as numbness in the lower limbs, that may help predict the need for immunosuppressive treatment. Further large-scale prospective studies are required to confirm these findings.</p>\u0000 </div>","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"53 8","pages":"1162-1169"},"PeriodicalIF":2.3,"publicationDate":"2026-08-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148166341","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness of Amenamevir Vs. Valacyclovir in Preventing Herpes Zoster-Related Hospitalization and Complications: A Target Trial Emulation Using a Large Japanese Claims Database","authors":"Yasuhiro Kano,&nbsp;Yuya Kimura,&nbsp;Hideo Yasunaga","doi":"10.1111/1346-8138.70349","DOIUrl":"10.1111/1346-8138.70349","url":null,"abstract":"<p>Amenamevir is a novel anti-herpes zoster drug that is increasingly used in Japan because of its once-daily administration and lack of renal dose adjustment requirements. However, evidence of its clinical effectiveness is limited. This study aimed to estimate the clinical effectiveness of amenamevir vs. valacyclovir in preventing zoster-related hospitalizations and complications. Using a nationally representative claims database from 2017 to 2024, we conducted a retrospective cohort study with a new-user, active-comparator design. We included adults (aged ≥ 18 years) with uncomplicated herpes zoster who initiated amenamevir or valacyclovir treatment. Propensity score overlap weighting was used to adjust for differences between patients prescribed amenamevir and valacyclovir. The primary outcome was 30-day zoster-related hospitalization. The secondary outcomes included diagnoses of zoster-related complications (zoster encephalitis, zoster meningitis, disseminated zoster, and zoster ocular disease) and acute kidney injury. In total, 67 912 individuals (38.2% male; mean age, 70.1 years) were included. After overlap weighting, baseline covariates were well-balanced between the groups. The risk of 30-day zoster-related hospitalization was similar between amenamevir and valacyclovir users (0.73% vs. 0.73%; risk ratio [RR], 1.00; 95% confidence interval [CI], 0.84–1.20). For secondary outcomes, zoster encephalitis (0.02% vs. 0.01%; RR, 2.09; 95% CI, 0.62–7.10), zoster meningitis (0.04% vs. 0.02%; RR, 2.32; 95% CI, 0.89–6.09), and disseminated zoster (0.13% vs. 0.10%; RR, 1.25; 95% CI, 0.79–1.97) did not differ significantly between the groups. However, amenamevir was associated with a higher risk of zoster ocular disease (0.84% vs. 0.67%; RR, 1.25; 95% CI, 1.05–1.49) and a lower risk of acute kidney injury (0.02% vs. 0.09%; RR, 0.23; 95% CI, 0.10–0.53). Based on our findings, amenamevir may be a useful option for herpes zoster, particularly in clinical settings where timely assessment of renal function is not available. However, caution is warranted regarding possible increases in ocular complications.</p>","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"53 8","pages":"1115-1123"},"PeriodicalIF":2.3,"publicationDate":"2026-08-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1346-8138.70349","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148214049","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Extended-Interval Dosing and Discontinuation of Dupilumab in Atopic Dermatitis: A Real-World Retrospective Study","authors":"Ryo Saito,&nbsp;Wataru Sasaki,&nbsp;Haruka Watanabe,&nbsp;Momoka Hashimoto,&nbsp;Rina Kamigaki,&nbsp;Kento Nagiri,&nbsp;Akio Tanaka","doi":"10.1111/1346-8138.70350","DOIUrl":"10.1111/1346-8138.70350","url":null,"abstract":"<p>This retrospective study evaluated the clinical courses and treatment patterns of 81 patients with atopic dermatitis (AD) treated with dupilumab at Hiroshima University Hospital. Patients were categorized into six groups based on their clinical outcomes, including those who continued treatment, achieved remission and discontinued, or discontinued due to adverse effects or insufficient efficacy. Of the 81 patients, 38 (47%) continued treatment throughout the study period, and 16 (20%) achieved remission and discontinued treatment without relapse. Analysis of baseline severity using EASI and TARC levels revealed no significant differences between these groups, suggesting that baseline severity does not predict long-term therapeutic outcomes. Regarding concomitant topical therapy, although the potency of topical corticosteroids (TCS) remained unchanged in most patients, the total dosage was significantly reduced by a mean of 71.3%, reflecting a successful transition to proactive therapy or a reduced affected body surface area. Furthermore, this study investigated the feasibility of extending dupilumab dosing intervals. Nearly half of the patients extended their intervals including every 3 weeks (Q3W), Q4W, and up to Q8W by 6 months without exacerbation. By 12 months, 22 of the 40 evaluable patients successfully transitioned to extended intervals up to Q12W. These findings suggest that baseline disease severity does not necessarily predict the long-term clinical course of dupilumab therapy in patients with AD. Although TCS potency is often maintained to ensure stability, the dosage can be drastically reduced. Furthermore, a subset of patients can discontinue or extend the dosing intervals, and the optimal timing for extending intervals is more flexible and can be initiated earlier than currently suggested by previous reports.</p>","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"53 8","pages":"1179-1183"},"PeriodicalIF":2.3,"publicationDate":"2026-08-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1346-8138.70350","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148229919","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Analysis of Phosphorylated MEK1 Expression Pattern in Cutaneous Dilated Vessels of Capillary Malformations","authors":"Michihiro Takiwaki,&nbsp;Kayo Kunimoto,&nbsp;Yumi Nakatani,&nbsp;Ken Miyazaki,&nbsp;Tokiyoshi Ikoma,&nbsp;Kana Sakai,&nbsp;Yuna Noda,&nbsp;Yutaka Inaba,&nbsp;Yuki Yamamoto,&nbsp;Masatoshi Jinnin","doi":"10.1111/1346-8138.70355","DOIUrl":"10.1111/1346-8138.70355","url":null,"abstract":"<div>\u0000 \u0000 <p>The mechanism of capillary malformation (CM) is thought to be the abnormal dilation of capillaries as a result of activation of the RAS–RAF–MEK–ERK pathway due to GNAQ/GNA11 gene mutations. However, no prior studies have actually demonstrated phosphorylation of MEK in CM. CMs were classified into three types according to clinical and histopathological findings: Flat, hypertrophic, and nodular. Comparison of the expression pattern of phosphorylated MEK1 (p-MEK1) in these three types of CMs revealed that p-MEK1 staining was positive in dilated capillaries in the upper dermis of the flat CMs. Double staining was performed to determine which cells of CM expressed p-MEK1: CD34 and p-MEK1 showed partial co-localization, demonstrating that p-MEK1 is expressed in the vascular endothelial cells. Both p-MEK1-positive and p-MEK1-negative vessels were observed in dilated vessels of CM. In addition, p-MEK1-positive vessels may be present deeper than anticipated. JNK and ERK were also phosphorylated in the dilated vessels. Furthermore, in contrast to the flat type and hypertrophic type of CM, the nodular type showed no p-MEK1 expression in its proliferated capillaries, supporting the notion that nodular CMs arise via a distinct mechanism. Taken together, our results indicated that visualization of affected vessels of CM using p-MEK1 immunostaining is useful not only for diagnosis but also for understanding the pathogenesis of CM.</p>\u0000 </div>","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"53 8","pages":"1170-1178"},"PeriodicalIF":2.3,"publicationDate":"2026-08-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148261320","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Serum N-Glycan Ratio Associated With Disease Severity and Treatment Response in Psoriasis","authors":"Kentarou Nishimura,&nbsp;Noritaka Oyama,&nbsp;Takumi Hasegawa,&nbsp;Hiroshi Kasamatsu,&nbsp;Takenao Chino,&nbsp;Takahiro Tokunaga,&nbsp;Kiyoshi Higashi,&nbsp;Koichi Saito,&nbsp;Keita Yamada,&nbsp;Minoru Hasegawa","doi":"10.1111/1346-8138.70316","DOIUrl":"10.1111/1346-8138.70316","url":null,"abstract":"<p>Psoriasis is a chronic, immune-mediated inflammatory disease with heterogeneous manifestations. Reliable biomarkers reflecting disease severity and treatment response remain limited. Glycans—carbohydrate structures attached to proteins and lipids—play key roles in biological processes, contributing to functional specificity. Abnormal glycosylation has been implicated in the pathogenesis of inflammatory and neoplastic diseases, highlighting their potential as therapeutic targets and biomarkers. This study aimed to evaluate serum N-glycan profiles as potential biomarkers for psoriasis, focusing on the ratio of sialylated biantennary N-glycan (S) to fucosylated asialo-biantennary N-glycan (FA), termed the S/FA ratio. Serum samples from 45 patients with psoriasis, 12 with atopic dermatitis (AD), and 19 healthy controls were analyzed using high-performance liquid chromatography. The performance of the S/FA ratio was compared with reported biomarkers (CRP and CCL20), and its associations with Psoriasis Area and Severity Index (PASI) and treatment response were examined. The S/FA ratio was significantly higher in psoriasis than in healthy controls (<i>p</i> &lt; 0.001) and correlated with PASI (<i>r</i> = 0.485, <i>p</i> &lt; 0.001) and its components. Receiver operating characteristic analysis showed comparable diagnostic accuracy among the S/FA ratio (AUC = 0.788, sensitivity: 73.7%, specificity: 73.3%), CRP (AUC = 0.780), and CCL20 (AUC = 0.741). Changes in the S/FA ratio were correlated with improvements in PASI after systemic treatment (<i>r</i> = 0.467, <i>p</i> = 0.002), including a patients subgroup receiving IL-23 inhibitors. The S/FA ratio was not significantly influenced by demographics, comorbidities, or arthralgia. No significant difference was observed between psoriasis and AD, and the S/FA ratio was not significantly elevated in AD compared with healthy controls. The serum S/FA ratio may serve as a glycan-based biomarker associated with disease severity and treatment response in psoriasis, although its ability to distinguish psoriasis from other inflammatory diseases requires further validation in larger and treatment-naïve cohorts.</p>","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"53 8","pages":"1090-1098"},"PeriodicalIF":2.3,"publicationDate":"2026-08-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1346-8138.70316","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148311161","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of Adjuvant Interferon-β Versus Observation for Resected Nail Apparatus Melanoma: A Multicenter Retrospective Study","authors":"Takaya Komori,&nbsp;Eiji Nakano,&nbsp;Yukiko Kiniwa,&nbsp;Shoichiro Mori,&nbsp;Sotaro Yamamoto,&nbsp;Hiroshi Kato,&nbsp;Shusuke Yoshikawa,&nbsp;Koji Yoshino,&nbsp;Megumi Aoki,&nbsp;Tatsuya Takenouchi,&nbsp;Takuya Maeda,&nbsp;Keijun Yoshino,&nbsp;Shuichi Ohe,&nbsp;Kenta Nakama,&nbsp;Hideyuki Ishikawa,&nbsp;Yoshiyuki Nakamura,&nbsp;Toshihiro Takai,&nbsp;Takamichi Ito,&nbsp;Hiroshi Kitagawa,&nbsp;Hiraku Kokubu,&nbsp;Naohito Hatta,&nbsp;Takeru Funakoshi,&nbsp;Toshihiko Hoashi,&nbsp;Takayuki Suyama,&nbsp;Susumu Fujiwara,&nbsp;Mamiko Masuzawa,&nbsp;Hiroshi Uchi,&nbsp;Takuya Miyagawa,&nbsp;Soichiro Kado,&nbsp;Yuki Yamamoto,&nbsp;Jun Asai,&nbsp;Junji Kato,&nbsp;Taku Maeda,&nbsp;Natsuki Baba,&nbsp;Yukihiko Kato,&nbsp;Kohei Oashi,&nbsp;Takeo Maekawa,&nbsp;Shunichi Jinnai,&nbsp;Aya Nishizawa,&nbsp;Ko Kagoyama,&nbsp;Atsushi Otsuka,&nbsp;Katsuhiko Nishihara,&nbsp;Dai Ogata,&nbsp;Kenjiro Namikawa,&nbsp;Yasuhiro Nakamura,&nbsp;Shigeto Matsushita","doi":"10.1111/1346-8138.70375","DOIUrl":"10.1111/1346-8138.70375","url":null,"abstract":"<p>Nail apparatus melanoma (NAM) is a biologically and clinically distinct subtype of melanoma; however, the efficacy of adjuvant interferon (IFN) therapy in this population remains unclear. We conducted a multicenter retrospective study to compare adjuvant IFN-β (adj-IFN) with observation (OBS) in patients with resected stage IIB, IIC, or III NAM. We analyzed 282 Japanese patients treated at 42 institutions between 2014 and 2024. Recurrence–free survival (RFS) and distant metastasis–free survival (DMFS) were co-primary outcomes, and overall survival (OS) was a secondary outcome. Survival outcomes were assessed using Kaplan–Meier analyses and Cox multivariable proportional hazards models. To minimize the differences of baseline characteristics between the two groups, propensity score matching (PSM) was applied. In multivariable Cox analyses, adj-IFN showed improved RFS (HR 0.67, 95% CI 0.45–0.998, <i>p</i> = 0.049), while no statistically significant benefits were observed for DMFS (HR 0.66, 95% CI 0.42–1.01, <i>p</i> = 0.06) or OS (HR 0.85, 95% CI 0.54–1.35, <i>p</i> = 0.50) compared with OBS. After PSM (71 patients per group), survival outcomes were comparable between the two groups, with no statistical significance in RFS (HR 0.71, 95% CI 0.45–1.12, <i>p</i> = 0.14), DMFS (HR 0.73, 95% CI 0.44–1.20, <i>p</i> = 0.22), or OS (HR 1.01, 95% CI 0.58–1.78, <i>p</i> = 0.96). In conclusion, no significant survival advantage of adj-IFN over observation was demonstrated in the matched cohort. Although a borderline association with improved RFS was observed in the overall cohort, this finding did not translate into consistent benefit across endpoints. Further prospective evidence, including the final results of the randomized phase III trial (JCOG1309, J-FERON), is required to clarify the clinical role of adj-IFN in NAM.</p>","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"53 8","pages":"1124-1132"},"PeriodicalIF":2.3,"publicationDate":"2026-08-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1346-8138.70375","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148400352","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}